Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of NOX-A12 with bortezomib + dexamethasone in relapsed multiple myeloma
2011-004651-40Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Nov 2011
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaptesed pegol in multiple myeloma (MM) (2 arms), sponsored by TME Pharma. Primary endpoint: Safety. Started Nov 2011; status: completed.
02
Drugs
olaptesed pegol
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-004651-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004651-40.